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ARTICLE
Gene-Gene and Gene-Environment Interactions Involving
HLA-DRB1, PTPN22, and Smoking in Two Subsets of Rheumatoid
Arthritis
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Annette H. M. van der Helm-van Mil, Rene E. M. Toes, Tom W. Huizinga, Lars Klareskog, and
Lars Alfredsson, for the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) Study Group
Gene-gene and gene-environment interactions are key features in the development of rheumatoid arthritis (RA) and
other complex diseases. The aim of this study was to use and compare three different deﬁnitions of interaction between
the two major genetic risk factors of RA—the HLA-DRB1 shared epitope (SE) alleles and the PTPN22 R620W allele—in
three large case-control studies: the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study, the
North American RA Consortium (NARAC) study, and the Dutch Leiden Early Arthritis Clinic study (in total, 1,977 cases
and 2,405 controls). The EIRA study was also used to analyze interactions between smoking and the two genes. “Inter-
action” was deﬁned either as a departure from additivity, as interaction in a multiplicative model, or in terms of linkage
disequilibrium—for example, deviation from independence of penetrance of two unlinked loci. Consistent interaction,
deﬁned as departure from additivity, between HLA-DRB1 SE alleles and the A allele of PTPN22 R620W was seen in all
three studies regarding anti-CCP–positive RA. Testing for multiplicative interactions demonstrated an interactionbetween
the two genes only when the three studies were pooled. The linkage disequilibrium approach indicated a gene-gene
interaction in EIRA and NARAC, as well as in the pooled analysis. No interaction was seen between smoking and PTPN22
R620W. A new pattern of interactions is described between the two major known genetic risk factors and the major
environmental risk factor concerning the risk of developing anti-CCP–positive RA. The data extend the basis for a
pathogenetic hypothesis for RA involving genetic and environmental factors. The study also raises and illustrates principal
questions concerning ways to deﬁne interactions in complex diseases.
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Rheumatoid arthritis (RA [MIM 180300]) is a prototype of
an autoimmune disease with complex etiology that is as-
sumed to involve several genetic as well as environmental
factors. The clinical hallmark of RA is symmetrical inﬂam-
matory arthritis. The disease is more common among
women than men. The major risk factors that have so far
been reproducibly identiﬁed are genetic variations in the
major histocompatibility complex, class II, DR beta 1
(HLA-DRB1 [MIM 142857]) and protein tyrosine phos-
phatase (PTPN22 [MIM 600716])1–4 genes and one envi-
ronmental risk factor, smoking.5–8 With regard to all three
risk factors, the major effects have been seen in one subset
of RA, characterized by the presence of antibodies to ci-
trullinated proteins (anti-CCP), but not in the subset of
RA in which these antibodies are not detected.2,3,7,8 Re-
cently, a pronounced gene-environment interaction was
identiﬁed between smoking and HLA-DRB1 shared epi-
tope (SE) alleles.6–8 The demonstration of this gene-envi-
ronment interaction, together with immunological stud-
ies in animal models of arthritis, led us to form a new
etiologic hypothesis suggesting that smoking contributes
to citrullination and to triggering of anti-citrulline im-
munity, which is restricted by HLA-DRB1 SE alleles.7,9
Since the PTPN22 gene codes for a tyrosine phosphatase,
with a potential function in the regulation of T-cell and
B-cell activation, it is of obvious interest for the study of
the etiology of RA to know how this more recently de-
scribed risk gene interacts with the classical HLA-DRB1 SE
genes, as well as with smoking.
Studies of interaction among risk factors in the epide-
miological literature have classically beenperformedusing
a departure from the additivity model originally described
by Rothman, where a term—the attributable proportion
due to interaction (AP)—is used to quantify the contri-
bution of interaction to a disease risk, as compared with
the contribution of each of the two risk factors added to
each other.10–12 This method can also be used to quantify
gene-gene interactions for unlinked loci. An alternative
common method for quantifying gene-gene interactions
is based on the calculation of the two risk factors’ product
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term in a logistic-regression model (multiplicative or sta-
tistical interaction). Recently, anothermethod for detecting
gene-gene interaction, based on deviation from indepen-
dence of penetrance in two unlinked loci, was proposed.13
As reported in this article, we used these three methods
to calculate interactions between the HLA-DRB1 SE alleles
and PTPN22 risk allele (R620W) in three different major
case-control studies of RA: the Swedish Epidemiological
Investigation of Rheumatoid Arthritis (EIRA) study, the
North American RA Consortium (NARAC) study, and a
Dutch case-control study based on the Leiden early ar-
thritis cohort.5,14–17 We used the largest one of these, which
is also the one in which smoking information is the most
detailed (the EIRA study5–7,14), to calculate interaction be-
tween the PTPN22 risk allele and smoking, with regard
to the risk of anti-CCP–positive RA, using the departure-
from-additivity model. A signiﬁcant interaction between
HLA-DRB1 SE alleles and the PTPN22 R620W allele was
seen with all methods when the three studies were pooled,
but the departure-from-additivity model was able to iden-
tify interaction in each one of the studies analyzed sep-
arately, whereas the multiplicative model identiﬁed this
interaction only when the three studies were pooled. No
interaction was seen between smoking and PTPN22. This
new description of the interaction patterns among the
three major known risk factors of RA, which all work in
one but not the other major subset of the disease, provides
a basis for further etiologic investigations of this disease,
with an increased emphasis on T-cell activation and spec-
iﬁcity. In addition, the data illustrate the need for consid-
eration and comparison of different methods for calcu-
lating interactions in complex diseases.
Material and Methods
This report is based on data from three different studies: (1) the
EIRA, (2) the NARAC, and (3) the Leiden Early Arthritis Clinic
(Leiden EAC). In each study, ethical permission was obtained
from the relevant ethical committees, and all the participants
consented to contribute to the study.
In the EIRA study, we recruited cases and controls aged 18–70
years during May 1996 to December 2003 from a geographically
deﬁned area in the south and central regions of Sweden. A case
was deﬁned as a person in the study base who was given a ﬁrst-
time diagnosis of RA, according to the American College of Rheu-
matology (ACR) criteria of 1987,18 by rheumatologists at private
as well as general health care units in the participating area. Con-
trols were randomly selected from a continuously updated na-
tional population register, with consideration given to age, sex,
and living area. If the selected control was not traceable, reported
having RA, or refused to participate, a new control was selected
using the same procedure. More details about the study are de-
scribed in other reports of the EIRA study.5–7,14,19
The second study used in this report, the NARAC, consists of
affected sibling pairs who fulﬁlled the 1987 ACR criteria18 and
matched, unrelated controls recruited from the New York Cancer
Project. Details regarding NARAC are provided elsewhere.15,16
The third study used, the Leiden EAC, consists of patients with
conﬁrmed RA with early onset and hospital-based controls with
and without deep venous thrombosis. Details on the Leiden EAC
and the controls used are given elsewhere.17,20
Biological Parameters and Genotyping
Analysis of anti-CCP antibodies for samples from the EIRA study,
as well as for samples from the Leiden EAC, was made with the
Immunoscan-RA Mark2 ELISA, as described elsewhere.2,21 Cases
with serum antibody levels 125 U/ml were regarded as anti-CCP
positive. Rheumatoid factor status for cases was determined using
standard procedures. Antibodies toward CCP in NARAC cases
were measured using a second-generation commercial anti-CCP
ELISA (Inova Diagnostics). Cases with antibody levels 120 U/ml
were regarded as anti-CCP positive.
Genotyping procedure of the PTPN22 and HLA-DRB1 genes is
described in previous articles.2,4,7–9,22 Allocation to SE was based
on local guidelines as described elsewhere, with the HLA-DRB1
alleles DRB1*01, DRB1*04, and DRB1*10 deﬁned as SE alleles. For
simplicity of evaluation, we assumed a dominant A allele model
for the PTPN22 R620W polymorphism and a dominant SE allele
model. Subjects with SE alleles were classiﬁed as having single or
double SE alleles, for a separate evaluation of a potential gene-
dosage effect.
Smoking Information
Smoking was considered only for the EIRA study. On the basis of
self-reported information from the EIRA questionnaire, we di-
vided participants into “ever smokers” and “never smokers.” An
ever smoker was deﬁned as a person who had ever smoked cig-
arettes. A never smoker was deﬁned as a person who had never
smoked cigarettes, pipes, cigars, etc.
Statistical Analysis
We calculated odds ratios (ORs) and 95% CIs of developing anti-
CCP–positive RA and anti-CCP–negative RA associated with each
of the factors—PTPN22 R620W alleles, HLA-DRB1 SE alleles, and
smoking—by means of logistic-regression models. We estimated
their separate effects, as well as the effect of their simultaneous
presence. All analyses based on the EIRA study were adjusted for
the matching variables: age (10 categories), living area (11 cate-
gories), and sex, together with smoking and presence of HLA-
DRB1 SE alleles when appropriate. Analyses based on the NARAC
study or the Leiden EAC were adjusted for sex and age (using the
same categories as in EIRA).
Interaction effects between the presence of HLA-DRB1 SE and
PTPN22 R620W alleles were evaluated using three different ap-
proaches. First, interaction between presence of HLA-DRB1 and
PTPN22 R620W alleles was evaluated using departure from ad-
ditivity of effects as the interaction criteria (biological interac-
tion), as suggested by Rothman.10,11 To quantify the amount of
interaction in terms of departure from additivity of effects, the
AP was calculated together with the 95% CI.12 The AP is the pro-
portion of the incidence among persons exposed to two inter-
acting factors that is attributable to the interaction per se (i.e.,
reﬂecting their joint effect beyond the sum of their independent
effects). A more detailed description regarding explanation, def-
inition, and programs used to calculate AP with CIs is given
elsewhere.10,12,23 We assessed the AP for each study as well as the
pooled estimate when all studies were combined (with adjust-
ment for study). To investigate potential mechanistic pathways
further, we also calculated interaction effects between the pres-
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Table 1. ORs and 95% CIs for Developing Anti-CCP–
Positive RA Associated with Presence of PTPN22 and HLA-
DRB1 Alleles and with Smoking
Study and
Risk Factor
No. of
Cases/
Controls OR 95% CI ORa 95% CI
EIRA:
PTPN22 230/179 1.6b 1.3–2.1 1.7b 1.3–2.2
HLA-DRB1 SE 615/414 5.6b 4.4–7.2 5.8b 4.5–7.6
Smoking 520/479 1.8b 1.4–2.2 1.9b 1.5–2.4
NARAC:
PTPN22 113/116 2.8c 2.0–3.8 2.6c 1.8–3.7
HLA-DRB1 SE 311/314 11.3c 7.7–16.5 12.0c 8.0–17.9
Smoking 197/357 1.3c 1.0–1.7 1.3c 1.0–1.8
Leiden EAC:
PTPN22 58/154 1.8c 1.3–2.6 1.8c 1.2–2.7
HLA-DRB1 SE 202/308 5.6c 3.9–7.9 6.1c 4.1–8.9
NOTE.—Results are displayed for each study.
a All risk factor variables in the same logistic-regression model.
b OR adjusted for sex, age, and living area.
c OR adjusted for sex and age.
Table 2. ORs and 95% CIs for Developing Anti-CCP–
Negative RA Associated with Presence of PTPN22 and
HLA-DRB1 Alleles and with Smoking for the EIRA Study
Study and
Risk Factor
No. of
Cases/
Controls OR 95% CI ORa 95% CI
EIRA:
PTPN22 114/179 1.2b .9–1.5 1.2b .9–1.6
HLA-DRB1 SE 261/414 1.2b .9–1.5 1.2b .9–1.5
Smoking 264/479 .9b .7–1.2 .9b .7–1.2
NARAC:
PTPN22 22/116 1.9c 1.1–3.3 2.0c 1.1–3.4
HLA-DRB1 SE 58/314 3.1c 1.9–5.1 3.1c 1.9–5.1
Leiden EAC:
PTPN22 26/152 .9c .6–1.4 .9c .6–1.4
HLA-DRB1 SE 83/385 1.4c 1.0–2.0 1.4c 1.0–2.0
NOTE.—Results are displayed for each study.
a All risk factor variables in the same logistic-regression model.
b OR adjusted for sex, age, and living area.
c OR adjusted for sex and age.
ence of PTPN22 R620W alleles and smoking and between smok-
ing and the presence of HLA-DRB1 SE alleles, using the departure-
from-additivity–based method.
Second, interaction between presence of HLA-DRB1 and PTPN22
R620W alleles was evaluated using the cross-product of the risk
factors in a logistic-regression model as interaction criteria (mul-
tiplicative or statistical interaction).10,11 We also pooled the three
studies, to increase power to detect multiplicative interaction. In
the analysis ofmultiplicative interaction,we adjusted for age, living
area (only EIRA), and sex, as well as for study in the pooled analysis.
Third, we used a recently developed method to assess gene-
gene interaction, which is based on deviation from independence
of penetrance of two unlinked loci. This is referred to as the
“linkage disequilibrium (LD) statistic.”13 We also calculated x2 sta-
tistics to compare allele distribution in the different studies, for
cases and controls separately. We used SAS software forWindows,
version 9.1 (SAS Institute), to analyze the data.
Results
This report is based on a total of 1,977 cases and 2,405
controls, distributed across the different studies as follows:
EIRA, 1,183 cases and 793 controls; NARAC, 430 cases and
731 controls; and Leiden EAC, 364 cases and 881 controls.
The EIRA study mainly involved individuals born in
Sweden. When those born outside Sweden were also taken
into consideration, 97% were of white origin. Of the cases,
∼61% had anti-CCP–positive RA. The corresponding ﬁg-
ures for presence of anti-CCP in the NARAC and the Lei-
den EAC studies were 81% and 56%, respectively. As pub-
lished elsewhere,2,4 the A allele of PTPN22 R620W and the
HLA-DRB1 SE alleles were both associated with increased
risks of developing anti-CCP–positive RA, separately as well
as when analyzed simultaneously in the samemodel (table
1). In general, ORs calculated from the NARAC study were
higher than those calculated from the EIRA or the Leiden
EAC study. In NARAC, the A allele of PTPN22 R620W and
the HLA-DRB1 SE alleles were also associatedwith increased
ORs for anti-CCP–negative RA, although not at the mag-
nitude as those for anti-CCP–positive RA (table 2).
Interaction between PTPN22 Alleles and HLA-DRB1 SE,
Regarding Risk of Anti-CCP–Positive and Anti-CCP–Negative
RA
The cell frequencies for different combinations of HLA-
DRB1 and PTPN22 alleles for cases and controls in the
three studies are displayed in table 3. There was a high
resemblance in allele distribution for HLA-DRB1 and
PTPN22 in the three patient materials. The controls, how-
ever, differed in allele distribution both for HLA-DRB1 and
PTPN22, with higher prevalence regarding both HLA-
DRB1 SE alleles and the A allele of PTPN22 R620W in the
EIRA as compared with the NARAC ( ) and the Lei-P ! .001
den controls ( ).P ! .001
In the EIRA study, the OR of developing anti-CCP–pos-
itive RA for subjects having at least one copy of the A allele
of PTPN22 R620W and at least one HLA-DRB1 SE allele
was 9.9 (95% CI 6.8–14.3), compared with subjects with
the nonsusceptible GG genotype of PTPN22 R620W and
without HLA-DRB1 SE alleles (table 4). In the NARAC
study, ORs were higher than corresponding ORs based on
the EIRAmaterial. The overall results fromLeiden EACwere
similar to the results from the EIRA study. No signiﬁcant
risk for anti-CCP–positive RA was conferred by the R620W
A allele in individuals lacking the HLA-DRB1 SE allele,
although the pooled estimate for the three studies com-
bined was associated with a slightly increased risk (OR 1.4
[95% CI 1.0–2.1]). Since the results were similar for women
and men, we display results for both sexes combined only.
Quantiﬁcation of the interaction betweenHLA-DRB1 SE
and the PTPN22 R620W A allele, by means of calculating
the AP, showed that the interaction was statistically sig-
niﬁcant in all three studies (EIRA AP 0.5 [95% CI 0.3–0.7],
NARAC AP 0.7 [95% CI 0.5–0.9], Leiden EAC AP 0.4 [95%
CI 0.1–0.8], and pooled material AP 0.5 [95% CI 0.4–0.6]).
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Table 3. Presence or Absence of R620W PTPN22
Susceptible Allele and HLA-DRB1 SE Alleles for
Anti-CCP–Positive and Anti-CCP–Negative Cases and
Controls, by Study
Study Group, Population,
and HLA-DRB1 Status
No. (%) of Individuals with
No R620W
PTPN22
Susceptible Allele
Any R620W
PTPN22
Susceptible Allele
EIRA:
Anti-CCP–positive cases:
No SE 75 (10) 31 (4)
Any SE 416 (58) 199 (28)
Anti-CCP–negative cases:
No SE 142 (31) 59 (13)
Any SE 206 (45) 55 (12)
Controls:
No SE 284 (36) 95 (12)
Any SE 330 (42) 84 (10)
NARAC:
Anti-CCP–positive cases:
No SE 28 (8) 8 (2.3)
Any SE 206 (59.3) 105 (30.3)
Anti-CCP–negative cases:
No SE 20 (24) 5 (6)
Any SE 41 (49) 17 (21)
Controls:
No SE 348 (48) 69 (9)
Any SE 267 (37) 47 (6)
Leiden EAC:
Anti-CCP–positive cases:
No SE 28 (14) 9 (4)
Any SE 122 (59) 48 (23)
Anti-CCP–negative cases:
No SE 61 (39) 13 (8)
Any SE 70 (45) 13 (8)
Controls:
No SE 413 (47) 83 (9)
Any SE 316 (36) 69 (8)
We also investigated interaction between the HLA-DRB1
SE and the PTPN22 R620W A alleles, using formulas de-
scribing multiplicative interactions (table 4). We did not
ﬁnd evidence of a signiﬁcant multiplicative interaction be-
tween the susceptibility alleles in any of the studies ana-
lyzed separately. However, when we tested the pooled ma-
terial for evidence of a positive interaction term, we found
evidence of multiplicative interaction ( ) (table 4).Pp .025
We also found evidence of signiﬁcant gene-gene interaction
by using the LD statistic, which is a measure of deviance
from independent penetrance of two unlinked loci. We ob-
tained signiﬁcant P values for the pooled material (Pp
) (table 4) and the EIRA ( ) and NARAC (.027 Pp .02 Pp
) studies, but not for the Leiden EAC study ( )..035 Pp .76
The OR for the presence of the R620W A allele and two
HLA-DRB1 SE alleles was 25.7 (95% CI 17.0–38.9) when
compared with those lacking bothHLA-DRB1 SE alleles and
the PTPN22 R620W A allele (all studies combined) (table
5); the corresponding AP was 0.5 (CI 0.2–0.7). We did not
ﬁnd any statistically signiﬁcant increased ORs of anti-CCP–
negative RA regarding the PTPN22 R620W allele or HLA-
DRB1 SE alleles in the EIRA or the Leiden EAC studies.
Interaction between PTPN22 and Smoking, Regarding Risk of
Anti-CCP–Positive and Anti-CCP–Negative RA
A signiﬁcant interaction (signiﬁcantly increased AP) has
previously been demonstrated between HLA-DRB1 SE and
smoking, concerning the risk to develop anti-CCP–positive
RA.7 When we performed the same analysis for interaction
between the presence of different allelic forms of the
PTPN22 gene and smoking, no interaction between these
two susceptibility factors was observed (data not shown) for
either anti-CCP–positive or anti-CCP–negative RA.
Interaction among PTPN22, HLA-DRB1 SE, and Smoking,
Regarding Risk of Anti-CCP–Positive and Anti-CCP–Negative
RA
Finally, all three factors were added into an analysis of
their combined effects as susceptibility factors for anti-
CCP–positive RA and anti-CCP–negative RA in the EIRA
study. As shown in table 6 and ﬁgure 1, a complex pattern
of interactions was observed, with very high ORs for the
A allele of PTPN22 R620W in combination with HLA-
DRB1 SE alleles and very high ORs also for smoking in
combination with HLA-DRB1 SE alleles. Taken together,
ORs between 20 and 25 were observed for combinations
of HLA-DRB1 SE alleles, smoking, and the A allele of
PTPN22 R620W. No increased ORs for any of the risk fac-
tors or any of the combinations were seen for anti-CCP–
negative RA (table 6 and ﬁg. 1B). Sex-speciﬁc subanalysis
was performed in all the different studies reported. Strat-
iﬁcation by sex, however, demonstrated onlymarginal dif-
ferences in observed effects (data not shown).
Discussion
The major ﬁnding reported in this article is the presence
of an interaction between the two major genetic poly-
morphisms, HLA-DRB1 SE and PTPN22 R620W, for de-
veloping anti-CCP–positive RA. An additional ﬁnding is
the absence of an interaction between smoking and the
PTPN22 risk allele. A point for discussion raised in our
report and illustrated by our ﬁndings is that different
methods for quantifying interactions may yield quite dif-
ferent results and that different methods should be con-
sidered when analyzing interactions in complex diseases.
The current study uses data from three major case-con-
trol studies of different white populations—that is, the
Swedish EIRA study, the North American NARAC study,
and the Dutch Leiden EAC. In all three studies, HLA-DRB1
and PTPN22 genetic polymorphisms were previously
shown to be associated with an increased risk for anti-
CCP–positive, but not anti-CCP–negative RA.2,3,7,8 On the
basis of these ﬁndings, we calculated the interaction be-
tween the genes in the two subsets of RA.
When the departure-from-additivity model was used,
clear evidence of interaction was seen in all three studies
analyzed separately, as well as when analysis was done on
pooled data from all the studies. When the multiplicative
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Table 4. ORs for Developing Anti-CCP–Positive RA According to Presence or Absence of Minor R620W PTPN22 and
HLA-DRB1 SE Alleles
Deviation from
Presence or Absence of
Allele(s), by Study
No. of Cases/
Controls OR 95% CI AP (95% CI) Additivity Multiplicity
Independence
of Penetrance
EIRAa
R620W PTPN22 HLA-DRB1 SE .5 (.3–0.7) P ! .001 Pp .06 Pp .022
None None 75/284 1.0 …
None Any 416/330 5.0 3.7–6.7
Any None 31/95 1.2 .8–2.0
Any Any 199/84 9.9 6.8–14.3
NARACb
R620W PTPN22 HLA-DRB1 .7 (.5–.9) P ! .001 Pp .05 Pp .035
None None 28/348 1.0 …
None Any 206/267 9.3 6.0–14.3
Any None 8/69 1.5 .6–3.4
Any Any 105/47 30.2 17.6–51.9
Leiden EACb
R620W PTPN22 HLA-DRB1 SE .4 (.1–.7) Pp .0016 Pp .29 Pp .76
None None 28/413 1.0 …
None Any 122/316 5.7 3.7–8.9
Any None 9/83 1.5 .7–3.3
Any Any 48/69 11.0 6.4–19.0
All studiesc
R620W PTPN22 HLA-DRB1 SE .5 (.4–.6) P ! .001 Pp .025 Pp .027
None None 131/1,045 1.0 …
None Any 744/913 6.1 4.9–7.5
Any None 48/247 1.4 1.0–2.1
Any Any 352/200 13.2 10.2–17.2
NOTE.—Tests for interaction between these susceptible alleles according to three different methods. Results are displayed for the EIRA,
NARAC, and Leiden EAC studies separately, as well as pooled.
a OR adjusted for age, sex, and living area (only EIRA).
b OR adjusted for age and sex.
c OR adjusted for age, sex, and study.
model was used, evidence of a gene-gene interaction was
seen only when the three materials were pooled but not
when they were analyzed separately, suggesting a lack of
power to detect epistasis in each study separately. When
the LD method was used, the pooled analysis as well as
the separate analyses on EIRA and NARAC gave evidence
of interaction. Taken together, these data thus provide
strong evidence of the existence of a gene-gene interaction
between HLA-DRB1 SE alleles and the PTPN22 R620W al-
lele in increasing the risk for the development of anti-
citrulline antibody–positive RA.
The concept of interaction was discussed by Rothman
in connection to the introduction of the component cause
model.11 Referring to the concept of this model, intended
to explain causality, two risk factors can be independent
if no pathway to disease requires the involvement of both
risk factors. Alternatively, a biological interaction is con-
sidered to be present if there is at least one pathway toward
disease that requires the involvement of both risk factors.
Interaction in this sense is detected by comparing the ef-
fect among those exposed to both factors with the sum of
the effects attributed to each of the two factors per se. Thus,
“interaction,” as deﬁned by a deviation from additivity, has
a biological interpretation. When two contributory causes
are interacting, there exists a pathway to disease requiring
both factors. Thus, such interactions are relevant from a
mechanistic perspective. Application of the previously
described concept of additive interaction to the results
from the present study would imply that having antigen-
presenting cells with MHC class II molecules containing
SE alleles (component cause one) and T-cells with dys-
functional down-regulation associated with the PTPN22
R620W allele (component cause two) would increase dis-
ease manifestation more than the expected sum of each
separate cause. This interaction is seen entirely among the
anti-CCP–positive cases. The observed interaction thus in-
dicates the existence of a disease mechanism for anti-CCP
positive RA that requires the simultaneous presence of the
HLA-DRB1 SE alleles and the PTPN22 R620W allele.
An alternative common method for quantifying inter-
actions is based on the calculation of the two risk factors’
product term in a logistic-regressionmodel (multiplicative
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Table 5. ORs for Developing Anti-CCP–Positive RA According to Presence or Absence of
Minor R620W PTPN22 Allele and HLA-DRB1 SE Alleles
AP (95% CI)
Presence or Absence of
Allele(s), by Study
No. of Cases/
Controls OR 95% CI Single Double
EIRAa
R620W PTPN22 HLA-DRB1 SE .5 (.3–.7) .4 (.0–.8)
None None 75/284 1.0 …
None Single 249/269 3.6 2.7–5.0
None Double 167/61 11.3 7.6–16.9
Any None 31/95 1.2 .8–2.0
Any Single 126/67 7.9 5.3–11.8
Any Double 73/17 18.1 9.9–33.0
NARACb
R620W PTPN22 HLA-DRB1 SE .7 (.5–.9) .6 (.3–.9)
None None 28/348 1.0 …
None Single 110/224 5.8 3.6–9.1
None Double 96/43 28.3 16.4–49.1
Any None 8/69 1.5 .6–3.4
Any Single 57/38 20.0 11.1–36.2
Any Double 48/9 73.7 31.3–173.5
Leiden EACb
R620W PTPN22 HLA-DRB1 SE .4 (.1–.7) .5 (.04–1.0)
None None 28/413 1.0 …
None Single 92/263 5.1 3.2–8.0
None Double 30/53 8.7 4.7–15.9
Any None 9/83 1.5 .7–3.3
Any Single 37/57 9.8 5.5–17.5
Any Double 11/12 17.4 6.7–44.0
All studiesc
R620W PTPN22 HLA-DRB1 SE .5 (.4–.7) .5 (.2–.7)
None None 131/1,045 1.0 …
None Single 451/756 4.5 3.6–5.6
None Double 293/157 13.7 10.4–18.0
Any None 48/247 1.4 1.0–2.1
Any Single 220/162 10.3 7.8–13.6
Any Double 132/38 25.7 17.0–38.9
NOTE.—Tests for interaction between these susceptible alleles according to three different methods. Results
are displayed for the EIRA, NARAC, and Leiden EAC studies separately, as well as pooled.
a OR adjusted for sex, age, and living area.
b OR adjusted for sex and age.
c OR adjusted for sex, age, and study.
interaction). In relation to the notion of interaction given
above—that is, the existence of at least one pathway to-
ward disease that requires the involvement of both risk
factors—interaction may be detected by means of a de-
parture from the multiplicative model as well, though this
detection will have a lower sensitivity and higher speci-
ﬁcity in relation to the corresponding detection by means
of departure from additivity.
Both the additive and multiplicative models offer the
possibility to have additional terms in the model to adjust
for other factors (e.g., environmental factors). The ability
to adjust for additional factors may thus make these mod-
els more usable than the currently used LD method.
These analyses have been based on an analysis of three
different patient collections; therefore, it is important to
consider the differences among them, particularly with
regard to the appropriateness of combining the data for
some analyses. The case-control study (EIRA) that provides
one basis for this and previous5–7,14,19 investigations of risk
factors of RA was designed to capture all incident cases of
RA in a certain geographical region of Sweden and to use
age- and sex-matched controls randomly selected from the
population in the same area. The high recruitment rate
of both cases and controls14 suggests that selection bias in
both cases and controls is small and, thus, that results well
represent true values for a Swedish population with early
RA. The cases with RA in the NARAC study are prevalent
cases who were recruited from various U.S. hospitals after
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Table 6. ORs for Developing Anti-CCP–Positive or Anti-CCP–Negative RA
According to Presence or Absence of Minor R620W PTPN22 Allele, Presence
or Absence of HLA-DRB1 SE Alleles, and Being an Ever or Never Smoker
(Based on the EIRA Study)
Presence or Absence of Allele(s) and
Smoking Status, by Anti-CCP Status
No. of Cases/
Controls ORa 95% CI
Anti-CCP Positive
R620W PTPN22 HLA-DRB1 SE Smoking
None None Never 25/106 1.0 …
Any None Never 10/31 1.3 .6–3.2
None Single Never 68/111 2.7 1.6–4.7
Any Single Never 37/27 6.5 3.3–12.8
None Double Never 38/33 5.1 2.7–9.8
Any Double Never 23/6 18.1 6.5–50.1
None None Ever 50/178 1.3 .7–2.2
Any None Ever 21/64 1.5 .8–2.9
None Single Ever 181/158 5.4 3.3–8.9
Any Single Ever 89/40 11.3 6.2–20.5
None Double Ever 129/28 23.6 12.8–43.8
Any Double Ever 50/11 23.4 10.4–52.4
Anti-CCP Negative
R620W PTPN22 HLA-DRB1 SE Smoking
None None Never 65/109 1.0 …
Any None Never 21/31 1.0 .5–1.9
None Single Never 71/111 1.0 .6–1.5
Any Single Never 16/27 .9 .5–1.9
None Double Never 20/33 .9 .5–1.8
Any Double Never 5/6 1.4 .4–4.8
None None Ever 77/178 .7 .5–1.1
Any None Ever 38/64 1.0 .6–1.6
None Single Ever 96/158 1.0 .7–1.5
Any Single Ever 27/40 1.3 .7–2.3
None Double Ever 19/28 1.1 .6–2.2
Any Double Ever 7/11 1.1 .4–3.2
a OR adjusted for sex, age, and living area.
their diagnosis had been veriﬁed by a rheumatology spe-
cialist. Cases, who were of white origin, were selected on
the basis of the severity of their disease, which is associated
with presence of HLA-DRB1 SE alleles, which could explain
why we observe higher ORs in the NARAC study. The con-
trols were recruited from a healthy population in New York
during a cancer surveillance program, and individuals were
selected to match RA cases for age, sex, and ethnicity. The
RA cases in the EAC study are incident cases recruited from
the Leiden area, as described elsewhere,17 and the diagnosis
was conﬁrmed by a rheumatologist. The controls were re-
cruited from a matched hospitalized group that included a
high proportion of subjects with venous thrombosis.
The study design in EIRA allows us to interpret the ORs
as relative risks, which is not the case for NARAC or Leiden
EAC. The formula for calculating the AP contains relative
risk; hence, the estimated APs for the NARAC and the
Leiden EACmight be less accurate than those for the EIRA.
Concerning the interactions between smoking and the
HLA-DRB1 and PTPN22 genes, we restricted our analysis
to the EIRA material, since, in NARAC, the smoking infor-
mation was collected differently among cases (prevalent
cases with a long history of disease) and controls (from
another study). Also, since smoking was associated with
deep venous thrombosis in the Leiden EAC and a substan-
tial part of the Leiden controls suffered from it, inclusion
of this sample would have led to biased estimates.
In contrast to the previous demonstration of an inter-
action between smoking and HLA-DRB1 SE in EIRA,6,7 we
found no interaction (neither with the additive nor mul-
tiplicative models) between smoking and presence of the
PTPN22 R620W A allele. Further, none of these three sus-
ceptibility factors and neither of their combinations pro-
vided any signiﬁcantly increased risk for anti-CCP–nega-
tive RA in the EIRA material.
The two genes discussed in the present report do both
have functions related to activation of the adaptive im-
mune system. The main function of HLA-DR antigens is
to present antigens to T lymphocytes, whereas the protein
tyrosine phosphatase coded for by the PTPN22 gene ap-
pears to have important functions in setting the threshold
for T-cell activation,24 although other functions have also
been implicated for this enzyme.25 The fact that both these
genes are associated almost exclusively with the anti-CCP–
positive subset of RA, and the fact that the PTPN22R620W
A allele appears to contribute a risk mainly when HLA-
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Figure 1. Histograms on ORs for developing anti-CCP–positive
(A) and anti-CCP–negative (B) RA for different combinations of
absence or presence of R620W PTPN22, single or double HLA-DRB1
SE alleles, and smoking (based on the EIRA study).
DRB1 SE alleles are present, thus provide strong additional
evidence that MHC class II–dependent T-cell activation is
of central pathogenetic importance for the subset of RA
characterized by presence of anti-CCP antibodies. An eti-
ologic hypothesis has recently been proposed that may
explain the strong interaction between smoking andHLA-
DRB1 SE alleles—the proposition being that smokingmay
contribute to citrullination of proteins in the lung and
that immune activation against such posttranslationally
modiﬁed proteins may occur preferentially in individuals
carrying HLA-DRB1 SE alleles, since citrullination may
speciﬁcally increase the afﬁnity between a protein and an
SE-containing HLA-DR b chain.26 This hypothesis was
made even more attractive by the recent demonstrations
that citrullination of self-antigens may make them more
immunogenic and arthritogenic9 and that transfer of an-
tibodies to citrullinated ﬁbrinogen enhances the devel-
opment of antibody-transferred arthritis in mice.27 The
absence of interaction between smoking and presence of
the PTPN22 R620W A allele adds to the signiﬁcance of
the previous ﬁnding of SE-smoking interaction, since it is
now shown that interactions with smoking is speciﬁc to
HLA-DRB1 SE and is not seen for other genes related to
immune activation, at least not for PTPN22.
In amore general sense, the present and previous studies
of gene-gene and gene-environment interactions in RA
show how a given genetic polymorphism—such as the
R620W allele of PTPN22,which alone provides amoderate
OR thought to be typical for many risk genes in complex
diseases—can exert much more signiﬁcant effects in com-
bination with other risk factors—here, the HLA-DRB1 SE
alleles. The data also emphasize how an environmental
factor can interact with susceptibility genes in different
subsets of a disease. Our analysis also illustrates how in-
teraction between genetic variations, as well as environ-
mental risk factors, needs to be investigated in the context
of genetic and environmental risk factors described else-
where, to understand the complexity of complex diseases.
Acknowledgments
The EIRA study was supported by grants from the Swedish Med-
ical Research Council, the Swedish Council for Working Life and
Social Research, King Gustaf V’s 80-year foundation, the Swedish
Rheumatic Foundation, the Stockholm County Council, the in-
surance company Arbetsmarknadens Fo¨rsa¨kringsaktiebolag, and
the County of So¨rmland Research and Development Center. We
thank all participating controls and patients with RA and the
following people who recruited patients for EIRA: Ingeli Andre´-
asson, Landvetter; Eva Baecklund, Akademiska Hospital; Ann
Bengtsson and Thomas Skogh, Linko¨ping Hospital; BirgittaNord-
mark, Johan Bratt, and Ingia¨ld Hafstro¨m, Karolinska University
Hospital; Kjell Hudde´nius, Rheumatology Clinic (Stockholm);
Shirani Jayawardene, Bollna¨s Hospital; Ann Knight, Hudiksvall
Hospital and Uppsala University Hospital; Ido Leden, Kristianstad
Hospital; Go¨ran Lindahl, Danderyd Hospital; Bengt Lindell, Kal-
mar Hospital; Christin Lindstro¨m and Gun Sandahl, Sophiahem-
met; Bjo¨rn Lo¨fstro¨m, Katrineholm Hospital; Ingmar Petersson,
Spenshult Hospital; Christoffer Schaufelberger, Sahlgrenska Uni-
versity Hospital; Patrik Stolt, Va¨stera˚s Hospital; Berit Sverdrup,
Eskilstuna Hospital; Olle Svernell, Va¨stervik Hospital; and Tomas
Weitoft, Ga¨vle Hospital. For excellent data collection, we thank
Marie-Louise Serra and Lena Nise, who provided invaluable con-
tributions to the collection of data and maintenance of the da-
tabase. The NARAC is supported by National Institutes of Health
grants RO1 AR44422 and NO1-AR-2–2263 and by the National
Arthritis Foundation. In addition to the original recruiting in-
vestigators, we thank Marlena Kern, Annette Lee, Robert Lund-
sten, Lindsey Criswell, Michael Seldin, Christopher Amos, Elaine
Remmers, and Daniel Kastner, for their major ongoing contri-
butions to the data management and analysis of this collection.
The NARAC is indebted to the patients enrolled in this study, for
their generosity and continuing participation. The Leiden EAC is
supported by The Dutch National Arthritis Foundation (Natio-
naal Reumafonds) and the AutoCure organization.We alsowould
www.ajhg.org The American Journal of Human Genetics Volume 80 May 2007 875
like to thank Prof. Dr. F. R. Rosendaal, Department of Epidemi-
ology, Leiden University Medical Centre, for providing controls.
Web Resource
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for RA, HLA-DRB1, and PTPN22)
References
1. Gregersen PK, Silver J, Winchester RJ (1987) The shared epi-
tope hypothesis. Arthritis Rheum 30:1205–1213
2. Huizinga TWJ, Amos CI, van der Helm-van Mil AHM, Chen
W, van Gaalen FA, Jawaheer D, Schreuder GMT, Wener M,
Breedvald FC, Ahmad N, et al (2005) Reﬁning the complex
rheumatoid arthritis phenotype based on speciﬁcity of the
HLA-DRB1 shared epitope for antibodies to citrullinated pro-
teins. Arthritis Rheum 52:3433–3438
3. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karl-
son EW, Wolfe F, Kastner DL, Alfredsson L, Altshuler D, et al
(2005) Replication of putative candidate-gene associations
with rheumatoid arthritis in 14,000 samples from North
America and Sweden: association of susceptibility with
PTPN22, CTLA4, and PADI4. Am J Hum Genet 77:1044–1060
4. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chok-
kalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM,
Spoerke JM, et al (2004) A missense single-nucleotide poly-
morphism in a gene encoding a protein tyrosine phosphatase
(PTPN22) is associated with rheumatoid arthritis. Am J Hum
Genet 75:330–337
5. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I,
Klareskog L, Alfredsson L (2003) Quantiﬁcation of the inﬂu-
ence of cigarette smoking on rheumatoid arthritis: results
from a population based case-control study, using incident
cases. Ann Rheum Dis 62:835–841
6. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L (2004)
A gene-environment interaction between smoking and shared
epitope genes in HLA-DR provides a high risk of seropositive
rheumatoid arthritis. Arthritis Rheum 50:3085–3092
7. Klareskog L, Stolt P, Lundberg K, Ka¨llberg H, Bengtsson C,
Grunewald J, Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-
Dahlqvist S, et al (2006) A new model for an etiology of RA:
smoking may trigger HLA-DR (SE)-restricted immune reac-
tions to autoantigens modiﬁed by citrullination. Arthritis
Rheum 54:38–46
8. Linn-Rasker SP, van der Helm-van Mil AH, Van Gaalen FA,
Kloppenburg M, de Vries R, le Cessie S, Breedveld FC, Toes RE,
Huizinga TW (2006) Smoking is a risk factor for anti-CCP an-
tibodies only in rheumatoid arthritis patients that carry HLA-
DRB1 shared epitope alleles. Ann Rheum Dis 65:366–371
9. Lundberg K, Nijenhuis S, Vossenaar E, Palmblad K, van Ven-
rooij WJ, Klareskog L, Zendman AJ, Harris HE (2005) Citrul-
linated proteins have increased immunogenicity and arthri-
togenicity and their presence in arthritic joints correlates
with disease severity. Arthritis Res Ther 7:R458–R467
10. Ahlbom A, Alfredsson L (2005) Interaction: a word with two
meanings creates confusion. Eur J Epidemiol 20:563–564
11. Rothman KJ (2002) Epidemiology: an introduction. Oxford
University Press, New York
12. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom
A (2005) Calculating measures of biological interaction. Eur
J Epidemiol 20:575–579
13. Zhao J, Jin L, Xiong M (2006) Test for interaction between
two unlinked loci. Am J Hum Genet 79:831–845
14. Bengtsson C, Nordmark B, Klareskog L, Lundberg I, Alfreds-
son L, EIRA Study Group (2005) Socioeconomic status and
the risk of developing rheumatoid arthritis: results from the
Swedish EIRA study. Ann Rheum Dis 64:1588–1594
15. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Mon-
teiro J, Kern M, Criswell LA, Albani S, Nelson JL, et al (2001)
A genomewide screen in multiplex rheumatoid arthritis fam-
ilies suggests genetic overlap with other autoimmune dis-
eases. Am J Hum Genet 68:927–936
16. Jawaheer D, Lum RF, Amos CI, Gregersen PK, Criswell LA
(2004) Clustering of disease features within 512 multicase
rheumatoid arthritis families. Arthritis Rheum 50:736–741
17. Van Aken J, van Bilsen JH, Allaart CF, Huizinga TW, Breedveld
FC (2003) The Leiden Early Arthritis Clinic. Clin Exp Rheu-
matol 21:S100–S105
18. Arnett FC, Eworthy SM, Bloch DA, McShane DJ, Fries JF, Coo-
per NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al
(1988) The American Rheumatism Association 1987 revised
criteria for the classiﬁcation of rheumatoid arthritis. Arthritis
Rheum 31:315–324
19. Stolt P, Kallberg H, Lundberg I, Sjogren B, Klareskog L, Al-
fredsson L (2005) Silica exposure is associated with increased
risk of developing rheumatoid arthritis: results from the
Swedish EIRA-study. Ann Rheum Dis 64:582–586
20. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E (1997)
The Leiden Thrombophilia Study (LETS). Thromb Haemost
78:631–635
21. Ro¨nnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Kla-
reskog L, van Vollenhoven RF (2005) Longitudinal analysis
of anti-citrullinated antibodies (anti-CP) during 5 years fol-
low-up in early rheumatoid arthritis: anti-CP status is a stable
phenotype that predicts worse disease activity and greater
radiological progression. Ann Rheum Dis 64:1744–1749
22. Olerup O, Zetterquist H (1992) HLA-DR typing by PCR am-
pliﬁcation with sequence-speciﬁc primers (PCR-SSP) in 2
hours: an alternative to serological DR typing in clinical prac-
tice including donor-recipient matching in cadaveric trans-
plantation. Tissue Antigens 39:225–235
23. Hosmer DW, Lemeshow S (1992) Conﬁdence interval esti-
mation of interaction. Epidemiology 3:452–456
24. Lee AT, Li W, Liew A, Bombardier C, Weisman M, Massarotti
EM, Kent J, Wolfe F, Begovich AB, Gregersen PK (2005) The
PTPN22 R620W polymorphism associates with RF rheu-
matoid arthritis in a dose-dependent manner but not with
HLA-SE status. Genes Immun 6:129–133
25. Gregersen PK, Batliwalla F (2005) PTPN22 and rheumatoid ar-
thritis: gratifying replication. Arthritis Rheum 52:1952–1955
26. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns
E (2003) Cutting edge: the conversion of arginine to citrulline
allows for a high-afﬁnity peptide interaction with the rheu-
matoid arthritis associated HLA-DRB1*0401 MHC class II
molecule. J Immunol 171:538–541
27. Hill J, Wehrli B, Jevnikar AM, Bell DA, Cairns E (2003) Ci-
trullinated ﬁbrinogen induces arthritis in HLA–DRB1*0401
transgenic mice. Arthritis Rheum 48 Suppl 9:S348
